Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TFE3
REST API REST API
Homo sapiens
TFE3 is differentially expressed in 293 experiments: 136 organism parts: liver, adipose tissue, ... (134 more);, 194 disease states: normal, acute myeloid leukemia, ... (192 more);, 89 cell types 400 cell lines 35 compound treatments and 87 other conditions.
Synonyms bHLHe33, TFEA
Orthologs tfe3a (Danio rerio)   Q4H369_CIOIN (Ciona intestinalis)   TFE3_BOVIN (Bos taurus)   Tfe3 (Rattus norvegicus)   Tcfe3 (Mus musculus)   tfe3b (Danio rerio)   tfe3 (Xenopus laevis)   TFE3 (Canis familiaris)   Mitf (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term humoral immune response, DNA binding, regulation of transcription, DNA-dependent, cytoplasm, transcription, DNA-dependent, protein dimerization activity, positive regulation of transcription from RNA polymerase II promoter, nucleus, protein heterodimerization activity, positive regulation of transcription, DNA-dependent, regulation of osteoclast differentiation, sequence-specific DNA binding transcription factor activity, transcription regulatory region DNA binding
InterPro Term HLH_DNA-bd, bHLH_ZIP_TF_MiT/TFE
UniProt Accession B5MDQ7, P19532, B4DIA5
Gene-Disease Assocation RENAL CELL CARCINOMA, Xp11-ASSOCIATED; RCCX1, RENAL CELL CARCINOMA, PAPILLARY, 1; RCCP1
Search EB-eye ENSG00000068323
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (39 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
SW480
3
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
A549
2
E-GEOD-3202, E-GEOD-6013
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MCF-10A
2
E-GEOD-14990, E-TABM-420
MOLT4
2
E-MTAB-62, E-MTAB-37
394 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (51 experiments)

Factor Value U/D Experiments
mononuclear
2
E-GEOD-13987, E-GEOD-26672
2
2
E-TABM-145, E-TABM-130
M1 macrophage
1
E-GEOD-5099
n/a
1
E-MTAB-24
iPS cells from episomal vectors (Defined Factor sub-clone)
1
E-GEOD-20033
CD8 positive T-cell
1
E-GEOD-6338
83 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-1121, E-TABM-15, ... (59 experiments)

Factor Value U/D Experiments
acute lymphoblastic leukemia
3
E-MTAB-37, E-MTAB-62, E-GEOD-96
colorectal adenocarcinoma
2
E-MTAB-62, E-AFMX-5
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
control
2
E-GEOD-8121, E-GEOD-16363
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
188 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (25 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
none
5
6
E-TABM-782, E-TABM-868, E-GEOD-412, E-MEXP-1958, E-GEOD-2649, ... (11 experiments)
NaOH
1
1
E-MEXP-2590
filtered air
1
E-TABM-127
1,25-dihydroxyvitamin D3
1
1
E-GEOD-995
placebo
1
E-MEXP-1335
29 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, E-MEXP-2283, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-22541, E-GEOD-22148, E-TABM-147, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-763, E-MEXP-1996, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (29 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-9723, E-MEXP-561

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-7179

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-22541

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-17636, E-GEOD-4600, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-MEXP-548, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Stimulus or stress
studied in E-GEOD-7538

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Tissue
studied in E-GEOD-30573

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-4922

Processing time: 0.415 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM